Overview
Lipid Nanoparticles (LNPs) represent a cutting-edge approach in the fight against viral infections, particularly airborne pathogens like SARS-CoV-2. At Nanotreat Inc., our LNP-based inhibitors are designed to provide targeted, localized protection by neutralizing viruses in the nasal cavity before they can cause infection. This innovative technology has the potential to revolutionize how we prevent and treat viral diseases.
How LNP-Based Inhibitors Work
Our LNP-based inhibitors work by utilizing nanoparticles that are engineered to either trap viruses or interfere with their ability to infect host cells. The core concept involves two primary strategies:
Virus Trapping:
LNP-Trap Formulation: This formulation is designed to act as a decoy, binding to the virus’s spike protein, which is responsible for attaching to host cells. By capturing these spike proteins, the LNP-Trap prevents the virus from binding to and entering cells, effectively neutralizing the threat before it can establish an infection.
Mechanism: The LNP-Trap particles are surface-modified with ligands such as ACE2 peptides or monoclonal antibodies that specifically target and bind to the spike proteins of viruses like SARS-CoV-2. Once bound, the virus is rendered inactive, reducing the likelihood of infection and transmission.
Receptor Knockdown:
LNP-Trim Formulation: This approach involves the delivery of small interfering RNA (siRNA) via LNPs to knock down the expression of key receptors on host cells that viruses use to gain entry, such as ACE2 and TMPRSS2. By reducing the availability of these receptors, the LNP-Trim formulation limits the virus’s ability to infect cells.
Mechanism: The siRNA delivered by LNP-Trim specifically targets the mRNA of these receptors, leading to their degradation and preventing the synthesis of the corresponding proteins. This temporary but significant reduction in receptor availability provides a robust defense against viral entry.
Benefits of LNP-Based Inhibitors
Localized Protection:
Our LNP-based inhibitors deliver treatments directly to the nasal cavity, providing localized protection where airborne viruses often enter. This targeted method boosts effectiveness and reduces systemic exposure.
Broad-Spectrum Efficacy:
Safety and Biocompatibility:
Extensive testing has shown that our LNP formulations are biocompatible and safe for use in humans, with minimal side effects. The localized nature of the treatment further reduces the risk of systemic side effects.
Ease of Administration:
Our nasal spray formulations are easy to administer, making them accessible for a wide range of users, including those at high risk of viral infections, such as healthcare workers and immunocompromised individuals.
Current Research and Development
At Nanotreat Inc., our ongoing research focuses on optimizing the efficacy and safety of our LNP-based inhibitors. Key areas of investigation include:
Efficacy Testing:
We are conducting rigorous in vitro and in vivo studies to evaluate the effectiveness of LNP-Trap and LNP-Trim formulations against various viral strains, including SARS-CoV-2 and its variants.
Formulation Enhancements:
Our scientists are working on refining the LNP formulations to improve their stability, enhance their ability to bind to viral particles, and extend their retention time in the nasal cavity.
Clinical Trials:
We are progressing towards clinical trials to assess the performance of our LNP-based inhibitors in real-world scenarios, with a focus on both prophylactic and therapeutic applications.
MON – FRI 9AM-5PM CST
Sales | Support | Investor Relations
info@nanotreat.ca
Need help? send an e-mail
+1(431)222-3009
Any questions? Reach Us Anytime